Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider - Gilde Healthcare

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

5. Juli 2024
Katwijk & Spijkenisse (the Netherlands)

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in the healthcare market. Strengthening their joint position will further elevate service levels and product offerings of both companies. The combination aims to maintain current service offerings and respect existing organizations, brands and partners. Integration will be done carefully, with the existing management teams and no changes to operations in Katwijk and Spijkenisse.

Ronald Holtzer, CEO of EetgemakWe are excited to join forces with TotaalVERS, together we create a full-service “one stop shop” for our current and future customers.”

Ronald van der Leer, CEO of TotaalVERS: “This partnership marks an important milestone in our history and reaffirms our commitment to quality, service and innovation in the healthcare market and other channels.” 

*The combination of TotaalVERS and Eetgemak is subject to approval from the ACM

About TotaalVERS
Founded in 2004 in Spijkenisse, TotaalVERS is an integrated producer and supplier of convenience meals, ingredients and groceries. Praised for its high service level, the company serves care & cure clients in the South-West of the Netherlands. The company has a state-of-the-art production and warehouse facility housing c. 125 employees. For more information, visit the company’s website at www.totaalvers.nl

About Eetgemak
Eetgemak is a leading producer and supplier of fresh, made-to-order meals, meal components and dietary meals. The organization supplies the care & cure sector in the Netherlands with over 40k meals per day. Gilde invested in the company in 2019 and is supporting Eetgemak in the expansion of its market position, through growth in existing and new markets. For more information, visit the company’s website at www.eetgemakgroep.nl

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com

 

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
3. Juni 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
28. April 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
22. April 2025